Xencor Future Growth

Future criteria checks 1/6

Xencor's earnings are forecast to decline at 0.7% per annum while its annual revenue is expected to grow at 16.8% per year. EPS is expected to grow by 5.4% per annum.

Key information

-0.7%

Earnings growth rate

5.42%

EPS growth rate

Biotechs earnings growth	23.5%
Revenue growth rate	16.8%
Future return on equity	n/a
Analyst coverage	Good
Last updated	06 Nov 2025

Recent future growth updates

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 10

Recent updates

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 31% Share Price Rise

Sep 25

Xencor, Inc. (NASDAQ:XNCR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Mar 30

Some Confidence Is Lacking In Xencor, Inc. (NASDAQ:XNCR) As Shares Slide 27%

Feb 04

Xencor: Substantial Promise, Slow Progress

Jan 30

Is Xencor (NASDAQ:XNCR) Using Too Much Debt?

Dec 31

Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up

Dec 03

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 10

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Sep 12

Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Sep 12

Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)

Sep 06

Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?

Jul 13

Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Jun 16

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Mar 27

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Feb 27

Xencor: Standing Out With XmAb Technology

Feb 03

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Jan 05

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Nov 13

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Nov 10

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Aug 08

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Aug 12

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Aug 03

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Jun 03

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Feb 18

Earnings and Revenue Growth Forecasts

NasdaqGM:XNCR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	152	-205	-131	-157	8
12/31/2026	124	-208	-130	-169	12
12/31/2025	132	-138	-68	-119	12
9/30/2025	150	-131	-138	-133	N/A
6/30/2025	147	-171	-137	-131	N/A
3/31/2025	127	-208	-171	-162	N/A
12/31/2024	110	-233	-212	-202	N/A
9/30/2024	109	-213	-143	-134	N/A
6/30/2024	150	-191	-143	-133	N/A
3/31/2024	172	-146	-115	-104	N/A
12/31/2023	175	-133	-99	-78	N/A
9/30/2023	145	-119	-151	-121	N/A
6/30/2023	113	-128	-136	-94	N/A
3/31/2023	98	-140	-64	-12	N/A
12/31/2022	165	-55	-19	24	N/A
9/30/2022	297	30	72	111	N/A
6/30/2022	289	22	45	73	N/A
3/31/2022	327	109	2	19	N/A
12/31/2021	275	83	-33	-17	N/A
9/30/2021	163	-4	-75	-62	N/A
6/30/2021	179	24	-42	-26	N/A
3/31/2021	124	-64	-58	-44	N/A
12/31/2020	123	-69	-19	-5	N/A
9/30/2020	84	-83	-55	-42	N/A
6/30/2020	71	-80	-55	-44	N/A
3/31/2020	77	-61	80	93	N/A
12/31/2019	157	27	53	64	N/A
9/30/2019	165	36	56	67	N/A
6/30/2019	172	49	N/A	63	N/A
3/31/2019	153	39	N/A	-74	N/A
12/31/2018	41	-70	N/A	-80	N/A
9/30/2018	59	-45	N/A	-70	N/A
6/30/2018	30	-71	N/A	-63	N/A
3/31/2018	43	-53	N/A	-47	N/A
12/31/2017	46	-38	N/A	-34	N/A
9/30/2017	22	-55	N/A	-43	N/A
6/30/2017	30	-40	N/A	95	N/A
3/31/2017	84	15	N/A	98	N/A
12/31/2016	109	45	N/A	95	N/A
9/30/2016	103	40	N/A	107	N/A
6/30/2016	99	38	N/A	12	N/A
3/31/2016	34	-18	N/A	14	N/A
12/31/2015	28	-18	N/A	27	N/A
9/30/2015	12	-27	N/A	25	N/A
6/30/2015	9	-23	N/A	-20	N/A
3/31/2015	9	-19	N/A	-18	N/A
12/31/2014	10	-16	N/A	-21	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XNCR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XNCR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XNCR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XNCR's revenue (16.8% per year) is forecast to grow faster than the US market (10.4% per year).

High Growth Revenue: XNCR's revenue (16.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XNCR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/14 06:43
End of Day Share Price	2025/11/14 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xencor, Inc. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Peter Lawson	Barclays
Etzer Darout	Barclays
Zhiqiang Shu	Berenberg

Xencor Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Consensus revenue estimates fall by 18%

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Price target decreased by 7.0% to US$40.50

Consensus revenue estimates increase by 19%

Recent updates

Xencor, Inc. Presents Initial Data for XmAb819, a First-In-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 31% Share Price Rise

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release

Health Check: How Prudently Does Xencor (NASDAQ:XNCR) Use Debt?

Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

IBD Biologics And TL1A Programs Will Forge New Paths

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell Small Cap Comp Growth Index

Xencor, Inc. Announces Retirement of Nancy Valente as Chief Development Officer

Xencor Announces Positive Interim Results from First-In-Human Healthy Volunteer Study of Xmab942, A High-Potency Extended Half-Life Anti-Tl1a Antibody, in Development for Treatment of Inflammatory Bowel Disease

Is Xencor (NASDAQ:XNCR) A Risky Investment?

Xencor, Inc., Annual General Meeting, Jun 12, 2025

Xencor, Inc. (NASDAQ:XNCR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Xencor Appoints Todd Simpson to Board of Directors

Some Confidence Is Lacking In Xencor, Inc. (NASDAQ:XNCR) As Shares Slide 27%

Xencor: Substantial Promise, Slow Progress

Is Xencor (NASDAQ:XNCR) Using Too Much Debt?

Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up

Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates

Xencor, Inc. Doses First Subject in Phase 1/2 Study of XmAb®?942 in Development for Patients with Inflammatory Bowel Disease

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)

Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?

Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Consensus revenue estimates fall by 18%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Co-Founder recently sold US$294k worth of stock

Co-Founder notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Xencor: Standing Out With XmAb Technology

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Co-Founder notifies of intention to sell stock

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Price target decreased by 7.0% to US$40.50

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor Announces Planned Retirement of Senior Vice President John Kuch

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Consensus revenue estimates increase by 19%

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Co-Founder notifies of intention to sell stock

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Consensus EPS estimates fall by 20%

Insufficient new directors

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder recently sold US$183k worth of stock

Consensus revenue estimates decrease by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improves as stock rises 15%

Senior VP & Chief Medical Officer recently sold US$101k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations